Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis
2:04 PM April 27, 2016– FDA clears investigational new drug submission – Phase II Clinical Study initiated NASHVILLE, Tenn., April 27, 2016 /PRNewswire/ — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, announced today the addition of VASCULANTM to its pipeline. Cumberland has initiated the clinical development of VasculanTM (ifetroban) oral capsule for the treatment of systemic sclerosis. The U.S. Food and Drug Administration (FDA) has cleared Cumberland’s investigational new drug application
Read more